Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 476

1.

Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY).

White WB, Wakefield DB, Moscufo N, Guttmann CRG, Kaplan RF, Bohannon RW, Fellows D, Wolfson L.

Circulation. 2019 Oct 14. doi: 10.1161/CIRCULATIONAHA.119.041603. [Epub ahead of print] No abstract available.

PMID:
31607143
2.

Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study.

Oelsner EC, Balte PP, Bhatt SP, Cassano PA, Couper D, Folsom AR, Freedman ND, Jacobs DR Jr, Kalhan R, Mathew AR, Kronmal RA, Loehr LR, London SJ, Newman AB, O'Connor GT, Schwartz JE, Smith LJ, White WB, Yende S.

Lancet Respir Med. 2019 Oct 9. pii: S2213-2600(19)30276-0. doi: 10.1016/S2213-2600(19)30276-0. [Epub ahead of print]

PMID:
31606435
3.

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B.

Lancet. 2019 Sep 13. pii: S0140-6736(19)32135-X. doi: 10.1016/S0140-6736(19)32135-X. [Epub ahead of print]

PMID:
31533906
4.

Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.

Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB.

Clin J Am Soc Nephrol. 2019 Aug 16. pii: CJN.01380219. doi: 10.2215/CJN.01380219. [Epub ahead of print]

PMID:
31420350
5.

Refining the Association Between Body Mass Index and Atrial Fibrillation: G-Formula and Restricted Mean Survival Times.

Conner SC, Lodi S, Lunetta KL, Casas JP, Lubitz SA, Ellinor PT, Anderson CD, Huang Q, Coleman J, White WB, Benjamin EJ, Trinquart L.

J Am Heart Assoc. 2019 Aug 20;8(16):e013011. doi: 10.1161/JAHA.119.013011. Epub 2019 Aug 8.

6.

Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.

Bhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, Jacobs DR Jr, Kalhan R, O'Connor GT, Yende S, Sanders JL, Umans JG, Dransfield MT, Chaves PH, White WB, Oelsner EC.

JAMA. 2019 Jun 25;321(24):2438-2447. doi: 10.1001/jama.2019.7233.

PMID:
31237643
7.

Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension.

Sardar P, Bhatt DL, Kirtane AJ, Kennedy KF, Chatterjee S, Giri J, Soukas PA, White WB, Parikh SA, Aronow HD.

J Am Coll Cardiol. 2019 Apr 9;73(13):1633-1642. doi: 10.1016/j.jacc.2018.12.082.

PMID:
30947915
8.

Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association.

Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG, Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB, Wright JT Jr.

Hypertension. 2019 May;73(5):e35-e66. doi: 10.1161/HYP.0000000000000087.

PMID:
30827125
9.

Cigarette Smoking and Subclinical Peripheral Arterial Disease in Blacks of the Jackson Heart Study.

Clark D 3rd, Cain LR, Blaha MJ, DeFilippis AP, Mentz RJ, Kamimura D, White WB, Butler KR, Robertson RM, Bhatnagar A, Butler J, Correa A, Benjamin EJ, Hall ME.

J Am Heart Assoc. 2019 Feb 5;8(3):e010674. doi: 10.1161/JAHA.118.010674.

10.

History and Justification of a National Blood Pressure Measurement Validated Device Listing.

Cohen JB, Padwal RS, Gutkin M, Green BB, Bloch MJ, Germino FW, Sica DA, Viera AJ, Bluml BM, White WB, Taler SJ, Yarows S, Shimbo D, Townsend RR.

Hypertension. 2019 Feb;73(2):258-264. doi: 10.1161/HYPERTENSIONAHA.118.11990. No abstract available.

PMID:
30580681
11.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
12.

Nocturnal blood pressure measured by home devices: evidence and perspective for clinical application.

Asayama K, Fujiwara T, Hoshide S, Ohkubo T, Kario K, Stergiou GS, Parati G, White WB, Weber MA, Imai Y; International Expert Group of Nocturnal Home Blood Pressure.

J Hypertens. 2019 May;37(5):905-916. doi: 10.1097/HJH.0000000000001987.

PMID:
30394982
13.

Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.

White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP.

J Am Heart Assoc. 2018 Oct 16;7(20):e009114. doi: 10.1161/JAHA.118.009114.

14.

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council.

Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.

15.

Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes.

White WB.

Circulation. 2018 Sep 11;138(11):1127-1129. doi: 10.1161/CIRCULATIONAHA.118.036148. No abstract available.

PMID:
30354393
16.

Cardiovascular Safety of Febuxostat.

White WB, Gunawardhana L.

N Engl J Med. 2018 Oct 18;379(16):1584. doi: 10.1056/NEJMc1809736. No abstract available.

PMID:
30332566
17.

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.

Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB.

Am J Cardiol. 2018 Nov 1;122(9):1496-1505. doi: 10.1016/j.amjcard.2018.07.022. Epub 2018 Aug 4.

18.

Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.

White WB, Siddiqui E, Tat T, Franks B, Schermer CR.

J Am Soc Hypertens. 2018 Nov;12(11):768-778.e1. doi: 10.1016/j.jash.2018.08.001. Epub 2018 Aug 10.

PMID:
30181042
19.

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.

Agarwal R, Rossignol P, Garza D, Mayo MR, Warren S, Arthur S, Romero A, White WB, Williams B.

Am J Nephrol. 2018;48(3):172-180. doi: 10.1159/000492622. Epub 2018 Sep 3.

20.

Relationships among clinic, home, and ambulatory blood pressures with small vessel disease of the brain and functional status in older people with hypertension.

White WB, Jalil F, Wakefield DB, Kaplan RF, Bohannon RW, Hall CB, Moscufo N, Fellows D, Guttmann CRG, Wolfson L.

Am Heart J. 2018 Nov;205:21-30. doi: 10.1016/j.ahj.2018.08.002. Epub 2018 Aug 11.

PMID:
30145340
21.

Effects of a State- and Use-Dependent Nav1.7 Channel Blocker on Ambulatory Blood Pressure: A Randomized, Controlled Crossover Study.

Fong R, Ballow CH, Naik H, Steiner D, Palmer J, White WB.

J Clin Pharmacol. 2019 Jan;59(1):90-97. doi: 10.1002/jcph.1298. Epub 2018 Aug 24.

22.

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.

Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB.

Rheumatology (Oxford). 2019 Jan 1;58(1):61-69. doi: 10.1093/rheumatology/key245.

23.

Ambulatory blood pressure monitoring in the 21st century.

O'Brien E, White WB, Parati G, Dolan E.

J Clin Hypertens (Greenwich). 2018 Jul;20(7):1108-1111. doi: 10.1111/jch.13275.

24.

Harmonization of Respiratory Data From 9 US Population-Based Cohorts: The NHLBI Pooled Cohorts Study.

Oelsner EC, Balte PP, Cassano PA, Couper D, Enright PL, Folsom AR, Hankinson J, Jacobs DR Jr, Kalhan R, Kaplan R, Kronmal R, Lange L, Loehr LR, London SJ, Navas Acien A, Newman AB, O'Connor GT, Schwartz JE, Smith LJ, Yeh F, Zhang Y, Moran AE, Mwasongwe S, White WB, Yende S, Barr RG.

Am J Epidemiol. 2018 Nov 1;187(11):2265-2278. doi: 10.1093/aje/kwy139.

PMID:
29982273
25.

Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.

Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA.

Diabetes Care. 2018 Jul;41(7):1510-1515. doi: 10.2337/dc18-0109. Epub 2018 May 30.

PMID:
29848776
26.

Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.

Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad F.

J Am Heart Assoc. 2018 May 16;7(11). pii: e007649. doi: 10.1161/JAHA.117.007649.

27.

Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study.

Kamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, Fox ER, Rodriguez CJ, Keith RJ, Benjamin EJ, Butler J, Bhatnagar A, Robertson RM, Winniford MD, Correa A, Hall ME.

Circulation. 2018 Jun 12;137(24):2572-2582. doi: 10.1161/CIRCULATIONAHA.117.031912. Epub 2018 Apr 16.

28.

Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

Cavender MA, White WB, Liu Y, Massaro JM, Bergenstal RM, Mehta CR, Zannad F, Heller S, Cushman WC, Cannon CP.

Clin Cardiol. 2018 Aug;41(8):1022-1027. doi: 10.1002/clc.22960. Epub 2018 Aug 16.

29.

Cardiovascular Safety of the β3 -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.

White WB, Chapple C, Gratzke C, Herschorn S, Robinson D, Frankel J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Weber MA.

J Clin Pharmacol. 2018 Apr 12. doi: 10.1002/jcph.1107. [Epub ahead of print]

PMID:
29645285
30.

Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.

White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM; EXAMINE Investigators.

Am J Med. 2018 Jul;131(7):813-819.e5. doi: 10.1016/j.amjmed.2018.02.023. Epub 2018 Mar 23.

PMID:
29581078
31.

A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.

Weber MA, Chapple CR, Gratzke C, Herschorn S, Robinson D, Frankel JM, Ridder AM, Stoelzel M, Paireddy A, van Maanen R, White WB.

Blood Press Monit. 2018 Jun;23(3):153-163. doi: 10.1097/MBP.0000000000000320.

32.

Longitudinal microstructural changes of cerebral white matter and their association with mobility performance in older persons.

Moscufo N, Wakefield DB, Meier DS, Cavallari M, Guttmann CRG, White WB, Wolfson L.

PLoS One. 2018 Mar 19;13(3):e0194051. doi: 10.1371/journal.pone.0194051. eCollection 2018.

33.

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators.

N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.

34.

Clinical Precision in the Management of Hypertension: Improving Upon the "One-Size-Fits-All" Approach.

White WB.

J Am Coll Cardiol. 2018 Apr 17;71(15):1611-1613. doi: 10.1016/j.jacc.2018.01.075. Epub 2018 Mar 7. No abstract available.

35.

Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.

White WB, Kowey P, Diva U, Sostek M, Tummala R.

J Cardiovasc Pharmacol Ther. 2018 Jul;23(4):309-317. doi: 10.1177/1074248418760239. Epub 2018 Mar 4.

PMID:
29504415
36.

Cardiorenal Safety of OTC Analgesics.

White WB, Kloner RA, Angiolillo DJ, Davidson MH.

J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):103-118. doi: 10.1177/1074248417751070. Review.

37.

A New Era of Renal Denervation Trials for Patients With Hypertension?

Jalil F, White WB.

Am J Kidney Dis. 2018 May;71(5):615-618. doi: 10.1053/j.ajkd.2017.11.009. Epub 2018 Jan 17. No abstract available.

PMID:
29352604
38.

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):398-405. doi: 10.2215/CJN.05280517. Epub 2018 Jan 16.

39.

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.

Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.

J Hypertens. 2018 Apr;36(4):947-956. doi: 10.1097/HJH.0000000000001647.

40.

High-Intensity Cigarette Smoking Is Associated With Incident Diabetes Mellitus In Black Adults: The Jackson Heart Study.

White WB, Cain LR, Benjamin EJ, DeFilippis AP, Blaha MJ, Wang W, Okhomina V, Keith RJ, Al Rifai M, Kianoush S, Winniford MD, Robertson RM, Bhatnagar A, Correa A, Hall ME.

J Am Heart Assoc. 2018 Jan 12;7(2). pii: e007413. doi: 10.1161/JAHA.117.007413.

41.

Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks.

Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, Barr RG, Beaty TH, Becker AB, Beilby J, Bisgaard H, Bjornsdottir US, Bleecker E, Bønnelykke K, Boomsma DI, Bouzigon E, Brightling CE, Brossard M, Brusselle GG, Burchard E, Burkart KM, Bush A, Chan-Yeung M, Chung KF, Couto Alves A, Curtin JA, Custovic A, Daley D, de Jongste JC, Del-Rio-Navarro BE, Donohue KM, Duijts L, Eng C, Eriksson JG, Farrall M, Fedorova Y, Feenstra B, Ferreira MA; Australian Asthma Genetics Consortium (AAGC) collaborators, Freidin MB, Gajdos Z, Gauderman J, Gehring U, Geller F, Genuneit J, Gharib SA, Gilliland F, Granell R, Graves PE, Gudbjartsson DF, Haahtela T, Heckbert SR, Heederik D, Heinrich J, Heliövaara M, Henderson J, Himes BE, Hirose H, Hirschhorn JN, Hofman A, Holt P, Hottenga J, Hudson TJ, Hui J, Imboden M, Ivanov V, Jaddoe VWV, James A, Janson C, Jarvelin MR, Jarvis D, Jones G, Jonsdottir I, Jousilahti P, Kabesch M, Kähönen M, Kantor DB, Karunas AS, Khusnutdinova E, Koppelman GH, Kozyrskyj AL, Kreiner E, Kubo M, Kumar R, Kumar A, Kuokkanen M, Lahousse L, Laitinen T, Laprise C, Lathrop M, Lau S, Lee YA, Lehtimäki T, Letort S, Levin AM, Li G, Liang L, Loehr LR, London SJ, Loth DW, Manichaikul A, Marenholz I, Martinez FJ, Matheson MC, Mathias RA, Matsumoto K, Mbarek H, McArdle WL, Melbye M, Melén E, Meyers D, Michel S, Mohamdi H, Musk AW, Myers RA, Nieuwenhuis MAE, Noguchi E, O'Connor GT, Ogorodova LM, Palmer CD, Palotie A, Park JE, Pennell CE, Pershagen G, Polonikov A, Postma DS, Probst-Hensch N, Puzyrev VP, Raby BA, Raitakari OT, Ramasamy A, Rich SS, Robertson CF, Romieu I, Salam MT, Salomaa V, Schlünssen V, Scott R, Selivanova PA, Sigsgaard T, Simpson A, Siroux V, Smith LJ, Solodilova M, Standl M, Stefansson K, Strachan DP, Stricker BH, Takahashi A, Thompson PJ, Thorleifsson G, Thorsteinsdottir U, Tiesler CMT, Torgerson DG, Tsunoda T, Uitterlinden AG, van der Valk RJP, Vaysse A, Vedantam S, von Berg A, von Mutius E, Vonk JM, Waage J, Wareham NJ, Weiss ST, White WB, Wickman M, Widén E, Willemsen G, Williams LK, Wouters IM, Yang JJ, Zhao JH, Moffatt MF, Ober C, Nicolae DL.

Nat Genet. 2018 Jan;50(1):42-53. doi: 10.1038/s41588-017-0014-7. Epub 2017 Dec 22.

42.

High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB.

Diabetes Obes Metab. 2018 Mar;20(3):654-659. doi: 10.1111/dom.13136. Epub 2017 Nov 21.

43.

Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals.

White WB, Hewitt LA, Mehdirad AA.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):332-340. doi: 10.1002/cpdd.393. Epub 2017 Oct 11.

44.

The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study.

Tibuakuu M, Kamimura D, Kianoush S, DeFilippis AP, Al Rifai M, Reynolds LM, White WB, Butler KR, Mosley TH, Turner ST, Kullo IJ, Hall ME, Blaha MJ.

PLoS One. 2017 Sep 18;12(9):e0184914. doi: 10.1371/journal.pone.0184914. eCollection 2017.

45.

Functional reach of older adults: normative reference values based on new and published data.

Bohannon RW, Wolfson LI, White WB.

Physiotherapy. 2017 Dec;103(4):387-391. doi: 10.1016/j.physio.2017.03.006. Epub 2017 Apr 4.

46.

Severe and resistant hypertension in an older woman with claudication.

Gupta P, Hagberg R, Kaloudis E, Lucas A, Shah P, White WB.

J Am Soc Hypertens. 2017 Aug;11(8):475-479. doi: 10.1016/j.jash.2017.05.007. Epub 2017 Jun 1.

47.

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.

Johnson W, White WB, Sica D, Bakris GL, Weber MA, Handley A, Perez A, Cao C, Kupfer S, Saunders EB.

J Clin Hypertens (Greenwich). 2017 Jul;19(7):695-701. doi: 10.1111/jch.12993. Epub 2017 May 11.

48.

Timed mobility: description of measurement, performance, and dimensionality among older adults.

Bohannon RW, Wolfson LI, White WB.

Disabil Rehabil. 2018 Aug;40(17):2011-2014. doi: 10.1080/09638288.2017.1323028. Epub 2017 May 5. Erratum in: Disabil Rehabil. 2018 Sep;40(18):2226.

49.

Utility of ambulatory blood pressure monitoring for the management of hypertension.

Campbell PT, White WB.

Curr Opin Cardiol. 2017 Jul;32(4):365-372. doi: 10.1097/HCO.0000000000000399. Review.

PMID:
28306674
50.

Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).

Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA.

Circulation. 2017 May 16;135(20):1911-1921. doi: 10.1161/CIRCULATIONAHA.116.024632. Epub 2017 Feb 28.

PMID:
28246236

Supplemental Content

Loading ...
Support Center